

BIO IMAGING TECHNOLOGIES INC  
Form 10QSB  
May 14, 2004  
Table of Contents

---

**United States**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-QSB**

---

(Mark One)

**Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the quarterly period ended March 31, 2004

**Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No. 1-11182

---

**BIO-IMAGING TECHNOLOGIES, INC.**

(Exact Name of Small Business Issuer as Specified in Its Charter)

---

Delaware

11-2872047

Edgar Filing: BIO IMAGING TECHNOLOGIES INC - Form 10QSB

(State or Other Jurisdiction of

(I.R.S. Employer

Incorporation or Organization)

Identification No.)

826 Newtown-Yardley Road, Newtown, Pennsylvania 18940-1721

(Address of Principal Executive Offices)

(267) 757-3000

(Issuer's Telephone Number,

Including Area Code)

---

Check whether the Issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes:  No:

State the number of shares outstanding of each of the Issuer's classes of common stock, as of April 30, 2004:

| <u>Class</u>                      | <u>Number of Shares</u> |
|-----------------------------------|-------------------------|
| Common Stock, \$0.00025 par value | 10,774,889              |

Transitional Small Business Disclosure Format (check one): Yes:  No:

---

**Table of Contents**

BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

|   | <u>Page</u> |
|---|-------------|
| <b><u>PART I. FINANCIAL INFORMATION.</u></b>  |             |
| Item 1. <u>Financial Statements</u>   | 1           |
| <u>CONSOLIDATED BALANCE SHEETS as of March 31, 2004 and December 31, 2003 (unaudited)</u>                   | 2           |
| <u>CONSOLIDATED STATEMENTS OF INCOME For the Three Months Ended March 31, 2004 and 2003 (unaudited)</u>     | 3           |
| <u>CONSOLIDATED STATEMENTS OF CASH FLOWS For the Three Months Ended March 31, 2004 and 2003 (unaudited)</u> | 4           |
| <u>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</u>   | 5           |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>        | 10          |
| <u>Results of Operations</u>  | 12          |
| <u>Business Segments</u>  | 15          |
| <u>Liquidity and Capital Resources</u>  | 15          |
| <u>Changes to Critical Accounting Policies and Estimates</u>  | 17          |
| Item 3. <u>Controls and Procedures</u>  | 17          |
| <b><u>PART II. OTHER INFORMATION.</u></b>   |             |
| Item 6. <u>Exhibits and Reports on Form 8-K</u>   | 18          |
| <u>SIGNATURES</u>   | 19          |

**Table of Contents**

**PART I. FINANCIAL INFORMATION.**

**Item 1. Financial Statements.**

References in this Form 10-QSB to Bio-Imaging, we, us, or our refer to Bio-Imaging Technologies, Inc., a Delaware corporation, and its subsidiaries.

Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America have been condensed or omitted from the following consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission, although we believe that such financial disclosures are adequate so that the information presented is not misleading in any material respect. The following consolidated financial statements should be read in conjunction with the year-end consolidated financial statements and notes thereto included in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2003.

The results of operations for the interim periods presented in this Form 10-QSB are not necessarily indicative of the results to be expected for the entire fiscal year.

**Table of Contents****BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(unaudited)

|  | <b>March 31,<br/>2004</b> | <b>December 31,<br/>2003</b> |
|--|---------------------------|------------------------------|
| <b>ASSETS</b>  |                           |                              |
| Current assets:  |                           |                              |
| Cash and cash equivalents  | \$ 11,541,646             | \$ 13,289,453                |
| Accounts receivable, net   | 6,119,561                 | 4,429,117                    |
| Prepaid expenses and other current assets  | 649,872                   | 573,978                      |
| Deferred income taxes  | 1,397,770                 | 1,613,498                    |
| <b>Total current assets</b>  | <b>19,708,849</b>         | <b>19,906,046</b>            |
| Property and equipment, net  | 4,871,808                 | 4,661,720                    |
| Other assets   | 1,262,466                 | 1,338,848                    |
| <b>Total assets</b>  | <b>\$ 25,843,123</b>      | <b>\$ 25,906,614</b>         |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>   |                           |                              |
| Current liabilities:   |                           |                              |
| Accounts payable   | \$ 1,120,615              | \$ 984,997                   |
| Accrued expenses and other current liabilities   | 1,153,803                 | 1,602,806                    |
| Deferred revenue   | 3,050,204                 | 3,070,359                    |
| Current maturities of capital lease obligations and convertible note   | 1,237,883                 | 1,281,997                    |
| <b>Total current liabilities</b>   | <b>6,562,505</b>          | <b>6,940,159</b>             |
| Long-term capital lease obligations  | 617,277                   | 770,702                      |
| Deferred income taxes  | 661,018                   | 661,018                      |
| Other liability  | 117,102                   | 108,347                      |
| <b>Total liabilities</b>   | <b>7,957,902</b>          | <b>8,480,226</b>             |
| Stockholders' equity:  |                           |                              |
| Common stock - \$.00025 par value; authorized 18,000,000 shares, issued and outstanding 10,772,889 shares at March 31, 2004 and 10,710,481 shares at December 31, 2003 | 2,721                     | 2,678                        |
| Additional paid-in capital   | 20,937,267                | 20,873,968                   |
| Accumulated deficit  | (3,054,767)               | (3,450,258)                  |
| <b>Stockholders' equity</b>  | <b>17,885,221</b>         | <b>17,426,388</b>            |
| <b>Total liabilities and stockholders' equity</b>  | <b>\$ 25,843,123</b>      | <b>\$ 25,906,614</b>         |

See Notes to Consolidated Financial Statements



**Table of Contents****BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF INCOME**

(unaudited)

|  | <b>For the Three Months Ended<br/>March 31,</b> |                   |
|--|---|-------------------|
|  | <b>2004</b>                                     | <b>2003</b>       |
| Service revenues   | \$ 5,933,551                                    | \$ 5,096,702      |
| Reimbursement revenues   | 690,860   | 608,552           |
| <b>Total revenues</b>  | <b>6,624,411</b>                                | <b>5,705,254</b>  |
| <b>Cost and expenses:</b>  |   |                   |
| Cost of revenues   | 4,265,108                                       | 3,946,893         |
| General and administrative expenses  | 1,060,475                                       | 913,197           |
| Sales and marketing expenses   | 651,047   | 451,215           |
| <b>Total cost and expenses</b>   | <b>5,976,630</b>                                | <b>5,311,305</b>  |
| Income from operations   | 647,781   | 393,949           |
| Interest income (expense) - net  | 16,698  | (27,387)          |
| Income before income tax provision   | 664,479   | 366,562           |
| Income tax provision   | 268,988   | 110,000           |
| <b>Net income</b>  | <b>\$ 395,491</b>                               | <b>\$ 256,562</b> |
| Basic earnings per common share  | \$ 0.04   | \$ 0.03           |
| Weighted average number of common shares                                       | 10,745,125                                      | 8,548,655         |
| Diluted earnings per common share  | \$ 0.03   | \$ 0.03           |
| Weighted average number of common shares and dilutive common equivalent shares | 12,281,359                                      | 10,047,858        |

See Notes to Consolidated Financial Statements

**Table of Contents****BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS**

(unaudited)

|   | <b>For the Three Months Ended<br/>March 31,</b> |                     |
|---|---|---------------------|
|   | <b>2004</b>                                     | <b>2003</b>         |
| <b>Cash flows from operating activities:</b>  |   |                     |
| Net income  | \$ 395,491                                      | \$ 256,562          |
| Adjustments to reconcile net income to net cash (used in) provided by operating activities: |   |                     |
| Depreciation and amortization   | 428,446   | 241,521             |
| Provision for deferred income taxes   | 215,728   |                     |
| Bad debt provision  | (9,349)   |                     |
| Stock based compensation expense  | 3,426   |                     |
| Changes in operating assets and liabilities:  |   |                     |
| Increase in accounts receivable   | (1,681,095)                                     | (95,461)            |
| Increase in prepaid expenses and other current assets                                       | (75,894)  | (99,508)            |
| Decrease in other assets  | 11,648  | 26,607              |
| Increase in accounts payable  | 135,618   | 247,037             |
| Decrease in accrued expenses and other current liabilities                                  | (452,429)                                       | (122,915)           |
| (Decrease) increase in deferred revenue   | (20,155)  | 766,842             |
| Increase in other liabilities   | 8,755   |                     |
| <b>Net cash (used in) provided by operating activities</b>                                  | <b>(1,039,810)</b>                              | <b>1,220,685</b>    |
| <b>Cash flows from investing activities:</b>  |   |                     |
| Purchases of property and equipment   | (573,800)                                       | (380,720)           |
| <b>Net cash used in investing activities</b>  | <b>(573,800)</b>                                | <b>(380,720)</b>    |
| <b>Cash flows from financing activities:</b>  |   |                     |
| Payments under equipment lease obligations  | (155,872)                                       | (120,374)           |
| Payments under promissory note  | (41,667)  | (41,667)            |
| Proceeds from exercise of stock options   | 63,342  | 68,606              |
| <b>Net cash used in financing activities</b>  | <b>(134,197)</b>                                | <b>(93,435)</b>     |
| <b>Net (decrease) increase in cash and cash equivalents</b>                                 | <b>(1,747,807)</b>                              | <b>746,530</b>      |
| Cash and cash equivalents at beginning of period  | 13,289,453                                      | 2,563,266           |
| <b>Cash and cash equivalents at end of period</b>   | <b>\$ 11,541,646</b>                            | <b>\$ 3,309,796</b> |
| <b>Supplemental schedule of noncash investing and financing activities:</b>                 |   |                     |
| Equipment purchased under capital lease obligations   | \$  | \$ 135,000          |





**Table of Contents**

**BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1 - Basis of Presentation:

The financial statements included in this Form 10-QSB have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-KSB for the year ended December 31, 2003.

In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary for a fair presentation of our financial position as of March 31, 2004 and December 31, 2003 and the results of our operations and our cash flows for the three months ended March 31, 2004 and 2003.

Interim results are not necessarily indicative of results for the full fiscal year.

Note 2 Stock-Based Compensation:

At March 31, 2004, we have one stock-based employee compensation plan. We account for this plan under the recognition and measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and Related Interpretations. No stock-based employee compensation cost is reflected in net income, as all options granted under this plan as of March 31, 2004 had an exercise price equal to or greater than the fair market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if we had applied the fair value recognition provisions of FASB Statement No. 123, Accounting for Stock-Based Compensation, as amended by FASB Statement No. 148 Accounting for Stock-Based Compensation Transition and Disclosure, to account for stock-based employee compensation.

**Table of Contents****BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited)

|   | <b>For the three months<br/>ended March 31,</b> |             |
|---|---|-------------|
|   | <b>2004</b>                                     | <b>2003</b> |
| Net income, as reported   | \$ 395,491                                      | \$ 256,562  |
| Deduct: total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects | \$ 55,552                                       | \$ 77,567   |
| Pro forma net income  | \$ 339,939                                      | \$ 178,995  |
| Earnings per share:   |   |             |
| Basic as reported   | \$ 0.04   | \$ 0.03     |
| Basic pro forma   | \$ 0.03   | \$ 0.02     |
| Diluted as reported   | \$ 0.03   | \$ 0.03     |
| Diluted pro forma   | \$ 0.03   | \$ 0.02     |

We have an employment agreement with an executive officer that provided for the granting of 30,000 restricted shares of Common Stock to the executive officer on January 31, 2005. We accrued \$3,426 of stock based compensation expense during the three months ended March 31, 2004.

## Note 3 - Earnings Per Share:

Basic earnings per common share for the three months ended March 31, 2004 and 2003 was calculated based upon net income divided by the weighted average number of shares of our common stock, \$0.00025 par value, outstanding during the period. Diluted earnings per share for the three months ended March 31, 2004 and 2003 was calculated based upon net income divided by the weighted average number of shares of our common stock outstanding during the period, adjusted for dilutive securities using the treasury method.

Table of ContentsBIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIESNOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

The computation of basic earnings per common share and diluted earnings per common share was as follows:

|  | For the three months ended<br>March 31, |            |
|--|---|------------|
|  | 2004                                    | 2003       |
| Net income basic   | \$ 395,491                              | \$ 256,562 |
| Interest expense on convertible note   | 11,565                                  | 16,637     |
| Net income diluted   | \$ 407,056                              | \$ 273,199 |
| Denominator basic:   |   |            |
| Weighted average number of common shares                                       | 10,745,125                              | 8,548,655  |
| Basic earnings per common share  | \$ 0.04                                 | \$ 0.03    |
| Denominator diluted:   |   |            |
| Weighted average number of common shares                                       | 10,745,125                              | 8,548,655  |
| Common share equivalents of outstanding stock options                          | 1,402,077                               | 1,208,457  |
| Common share equivalents related to the convertible promissory note            | 134,157                                 | 290,746    |
| Weighted average number of common shares and dilutive common equivalent shares | 12,281,359                              | 10,047,858 |
| Diluted earnings per common share  | \$ 0.03                                 | \$ 0.03    |

As of March 31 2004, options to purchase 206,100 shares of our common stock have been excluded from the calculation of diluted earnings per common share as they are antidilutive. As of March 31, 2003, there are no stock options that are excluded from the calculation of diluted earnings per common share as they are all dilutive.

**Table of Contents**

**BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited)

Note 4 - Long-term Debt:

On May 9, 2003, we renewed and amended our agreement with Wachovia Bank, National Association. The renewed and amended agreement is for a committed line of credit of \$2,000,000, collateralized by our assets. Interest is payable at Wachovia Bank's prime rate. The agreement requires us, among other things, to maintain a debt service coverage ratio of not less than 1.25 to 1.00, measured annually and a liquidity ratio of not less than 2.00 to 1.00 at all times. The committed line of credit matures June 30, 2004 and may be renewed on an annual basis. At March 31, 2004, we had no borrowings under the committed line of credit and are compliant with the debt covenants.

On October 1, 2001, we acquired effective control of the Intelligent Imaging business unit of Quintiles, Inc., a North Carolina corporation, referred to as Quintiles, and a wholly-owned subsidiary of Quintiles Transnational Corporation. The acquisition of Intelligent Imaging closed on October 25, 2001. In connection with the acquisition of Intelligent Imaging, as of February 1, 2002, we are obligated to pay quarterly payments of principal of \$41,667 under a note, referred to as the Quintiles Note, plus accrued interest thereon, and one payment of principal of \$500,000 on November 1, 2004, unless the Quintiles Note is previously converted into shares of our common stock. The Quintiles Note bears interest at the rate in effect on the business day immediately prior to the date on which payments are due under the Quintiles Note equal to the three-month LIBOR (London Interbank Offering Rate) as published from time to time in The Wall Street Journal plus 3%, compounded annually based on a 365-day year. We have recorded the balance of the Quintiles Note of \$624,997 as a current liability as of March 31, 2004.

The number of shares of our common stock into which the Quintiles Note may be converted is calculated by dividing the outstanding principal balance of the Quintiles Note, plus all accrued and unpaid interest thereon, by the greater of: (i) 75% of the average closing price of our common stock over the ten consecutive trading days ending prior to the date of conversion; or (ii) \$0.906 per share. At March 31, 2004, the Quintiles Note would have been convertible into 134,823 shares of our common stock. This was calculated by dividing the unpaid principal balance (\$624,997 as of March 31, 2004) plus accrued interest (\$4,626 as of March 31, 2004), totaling \$629,623, by \$4.67 (75% of the average closing price of our common stock over the ten consecutive trading days ending on March 31, 2004). Under the formula contained in the Quintiles Note, at the minimum price per share of \$0.906, the maximum number of shares of our common stock to be issued to Quintiles, based upon the outstanding principal amount and accrued interest at March 31, 2004, would be 694,948 shares.

**Table of Contents****BIO-IMAGING TECHNOLOGIES, INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited)

## Note 5 Business Segments

FASB Statement No. 131, Disclosures about Segments of an Enterprise and Related Information, requires companies to provide certain information about their operating segments. In November 2003, we acquired the intellectual property of CapMed Corporation, accordingly, we now have two reportable segments: pharmaceutical contract services and CapMed. Our pharmaceutical contract service segment provides services that support the product development process of the pharmaceutical, biotechnology and medical device industries. Our CapMed segment offers a software application that enables users to manage and store personal health information, including their medical images, on the privacy of their desktop computer, while linking directly to sponsor-directed resources such as drug information, patient education, or disease guidelines. The operating segments are managed separately because each offers different services and applications to different markets. Our management evaluates performance based upon operating earnings or losses before interest and income taxes.

Summarized financial information concerning our reportable segments is shown in the following table:

| (in thousands)                            | <b>Pharmaceutical<br/>Contract<br/>Services</b> | <b>CapMed</b>               | <b>Consolidated<br/>Total</b> |
|---|---|-----------------------------|-------------------------------|
|   | <u>                    </u>                     | <u>                    </u> | <u>                    </u>   |
| For the three months ended March 31, 2004 |   |                             |                               |
| Total revenues                            | \$ 6,619  | \$ 5                        | \$ 6,624                      |
| Total cost and expenses                   | \$ 5,794  | \$ 182                      | \$ 5,976                      |
| Income (loss) from operations             | \$ 825  | \$ (177)                    | \$ 648                        |
| Segment assets at March 31, 2004          | \$ 24,988                                       | \$ 855                      | \$ 25,843                     |
| For the three months ended March 31, 2003 |   |                             |                               |
| Total revenues                            | \$ 5,705  |                             | \$ 5,705                      |
| Total cost and expenses                   | \$ 5,311  |                             | \$ 5,311                      |
| Income from operations                    | \$ 394  |                             | \$ 394                        |
| Segment assets at March 31, 2003          | \$ 12,630                                       |                             | \$ 12,630                     |

## **Table of Contents**

### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

#### **Overview**

We are a pharmaceutical contract service organization, providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. We specialize in assisting our clients in the design and management of the medical-imaging component of clinical trials for all imaging modalities, including computerized tomography, magnetic resonance imaging, x-rays, dual energy x-ray absorptiometry, position emission tomography, single photon emission computerized tomography and ultrasound. We provide services that include the processing and analysis of medical images and the data-basing and regulatory submission of medical images, quantitative data and text. We also offer a service called Bio-Imaging ET&C<sup>SM</sup>, which focuses on education, training and certification for medical imaging equipment, facilities and staff.

Our sales cycle, referring to the period from the presentation by us to a potential client to the engagement of us by such client, has historically been approximately 12 months. In addition, the contracts under which we perform services typically cover a period of 12 to 60 months and the volume and type of services performed by us generally vary during the course of a project. We cannot assure you that our project revenues will remain at levels sufficient to maintain profitability. Service revenues were generated from 64 clients encompassing 147 distinct projects for the three months ended March 31, 2004. This compares to 46 clients encompassing 115 distinct projects for the three months ended March 31, 2003.

Our contracted/committed backlog, referred to as backlog, is the amount of service revenue that remains to be earned and recognized on both signed and verbally agreed to contracts. Our backlog was approximately \$42.6 million as of March 31, 2004. This compares to approximately \$36.3 million as of March 31, 2003, an increase of 17.4%. Contracts included in backlog are subject to termination by our clients at any time. In the event that a contract is cancelled by the client, we would be entitled to receive payment for all services performed up to the cancellation date. The duration of the projects included in our backlog range from less than 3 months to 7 years. We believe that our backlog assists our management as an indicator of our long-term business. However, we do not believe that backlog is a reliable predictor of near-term results because service revenues may be incurred in a given period on contracts that were not included in the previous reporting period's backlog and/or contract cancellations may occur in a given period on contracts that were included in the previous reporting period's backlog.

We believe that demand for our services and technologies will continue to grow as the use of digital technologies for data acquisition and management increases in the radiology and drug development communities. We also believe that there is a growing recognition within the bio-pharmaceutical industry of the advantages in using an independent centralized core laboratory for analysis of medical-imaging data and compliance with the regulatory demands for the submission of such data. In addition, the FDA is gaining experience with electronic

**Table of Contents**

submissions and is continuing to develop sophisticated guidelines for computerized submission of clinical trial data, including medical images. Furthermore, the increased use of digital medical images in clinical trials, especially for important drug classes such as anti-inflammatory, neurologic and oncologic therapeutics and diagnostic image agents, generate large amounts of image data from a large number of imaging sources. These studies require processing, analysis, data management and submission services best handled by vendors with scalable logistical capabilities and extensive experience working with research facilities worldwide. Due to several factors, including, without limitation, competition from commercial competitors and academic research centers, we cannot assure you that demand for our services and technologies will grow, sustain growth, or that additional revenue generating opportunities will be realized by us.

In November 2003, we acquired the intellectual property of CapMed Corporation, located in Wilmington, Delaware, including the Personal Health Record software, referred to as PHR, and the patent-pending Personal HealthKey technology. The PHR is a software application that enables users to manage and store personal health information, including their medical images, on the privacy of their desktop computer, while linking directly to sponsor-directed resources such as drug information, patient education, or disease guidelines. The Personal HealthKey plugs into a computer's USB port, allowing doctors and patients easy access to the patient's medical record without the need for additional hardware or software, and it is password protected. The negotiations between us and CapMed were conducted on an arms-length basis. In connection with the acquisition, CapMed received aggregate consideration of \$550,000, consisting of \$211,828 in cash paid directly to CapMed's creditors and \$338,171 of our common stock, which amounted to a total of 51,724 shares, of which 40,361 were issued to CapMed and 11,363 were issued to an escrow agent pursuant to the terms of the acquisition.

We intend to expand our CapMed division through partnerships and marketing efforts devoted to the PHR and Personal HealthKey products. We believe that continued emphasis on improving patient care and reducing cost will contribute to the growth of the personal electronic medical records market.

Certain matters discussed in this Form 10-QSB are forward-looking statements intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as believes, expects, may, will, should, or anticipates or the negative thereof or other variations thereof, comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the demand for our services and technologies, growing recognition for the use of independent centralized core laboratories, trends toward the outsourcing of imaging services in clinical trials, realized return from our marketing efforts and increased use of digital medical images in clinical trials are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of revenues due to the variability in size, scope and duration of projects, estimates made by management with respect to our critical accounting policies, regulatory delays,



**Table of Contents**

clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within our control. The factors discussed in this Form 10-QSB and expressed from time to time in our filings with the Securities and Exchange Commission, as well as the risk factors set forth in our most recent Form 10-KSB, could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this filing and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Results of Operations****Three Months Ended March 31, 2004 and 2003**

|                                     | <b>Three Months</b> |                | <b>Three Months</b> |                | <b>\$ Change</b>  | <b>% Change</b> |
|-------------------------------------|---------------------|----------------|---------------------|----------------|-------------------|-----------------|
|                                     | <b>Ended</b>        | <b>% of</b>    | <b>Ended</b>        | <b>% of</b>    |                   |                 |
|                                     | <b>March 31,</b>    | <b>Total</b>   | <b>March 31,</b>    | <b>Total</b>   |                   |                 |
|                                     | <b>2004</b>         | <b>Revenue</b> | <b>2003</b>         | <b>Revenue</b> |                   |                 |
| Service revenues                    | \$ 5,933,551        | 89.6%          | \$ 5,096,702        | 89.3%          | \$ 836,849        | 16.4%           |
| Reimbursement Revenues              | \$ 690,860          | 10.4%          | \$ 608,552          | 10.7%          | \$ 82,308         | 13.5%           |
| <b>Total revenues</b>               | <b>\$ 6,624,411</b> | <b>100.0%</b>  | <b>\$ 5,705,254</b> | <b>100.0%</b>  | <b>\$ 919,157</b> | <b>16.1%</b>    |
| Cost of revenues                    | \$ 4,265,108        | 64.4%          | \$ 3,946,893        | 69.2%          | \$ 318,215        | 8.1%            |
| General and administrative expenses | \$ 1,060,475        | 16.0%          | \$ 913,197          | 16.0%          | \$ 147,278        | 16.1%           |
| Sales and marketing Expenses        | \$ 651,047          | 9.8%           | \$ 451,215          | 7.9%           | \$ 199,832        | 44.3%           |
| <b>Total cost and Expenses</b>      | <b>\$ 5,976,630</b> | <b>90.2%</b>   | <b>\$ 5,311,305</b> | <b>93.1%</b>   | <b>\$ 665,325</b> | <b>12.5%</b>    |
| Interest income (expense)-net       | \$ 16,698           | 0.3%           | \$ (27,387)         | (0.5)%         | \$ 44,085         | 161.0%          |
| Income before income tax provision  | \$ 664,479          | 10.0%          | \$ 366,562          | 6.4%           | \$ 297,917        | 81.3%           |
| Income tax provision                | \$ 268,988          | 4.1%           | \$ 110,000          | 1.9%           | \$ 158,988        | 144.5%          |
| <b>Net income</b>                   | <b>\$ 395,491</b>   | <b>6.0%</b>    | <b>\$ 256,562</b>   | <b>4.5%</b>    | <b>\$ 138,929</b> | <b>54.2%</b>    |

Service revenues for the three months ended March 31, 2004 and 2003 were \$5,933,551 and \$5,096,702, respectively, an increase of \$836,849 or 16.4%. The increase in service revenues was due to an increase in the number of projects resulting from the overall market growth for medical-imaging related services for clinical trials and what we believe to be our increasing market share.

**Table of Contents**

Service revenues were generated from 64 clients encompassing 147 distinct projects for the three months ended March 31, 2004. This compares to 46 clients encompassing 115 distinct projects for the three months ended March 31, 2003. Two clients, Eli Lilly and Company and Amgen Inc., encompassing 18 projects represented 21.8% of our service revenues for the three months ended March 31, 2004, while for the comparable period last year, two clients encompassing six projects represented 27.4% of our service revenues. No other client accounted for more than 10% of service revenues in each of the three-month periods ended March 31, 2004 and 2003. Service revenues generated from our client base, while still concentrated as measured by the number of clients, has continued to become more dispersed over time and we believe more diversification is evident when revenue concentration is measured by the number of individual projects. We believe that measuring revenue concentration by project diversification may be more indicative of revenue concentration risk since we are often working on several separately-based and funded projects with a single client, with each project often being wholly independent from the others. Our primary scope of work in both periods included medical-imaging core laboratory services and image-based information management services.

Reimbursement revenues consist of pass-through costs reimbursed by the customer. Reimbursement revenues fluctuate significantly over the course of any given project and quarter to quarter variations are a reflection of this project timing. Therefore, our management believes that reimbursement revenues are not a significant indicator of our overall performance trends.

Cost of revenues for the three months ended March 31, 2004 and 2003 was \$4,265,108 and \$3,946,893, respectively, an increase of \$318,215 or 8.1%. The increase in cost of revenues is substantially all due to the variable costs associated with the increase in staffing levels required for project related tasks due to the increase in revenues for the three months ended March 31, 2004. Cost of revenues for the three months ended March 31, 2004 and three months ended March 31, 2003 were comprised of professional salaries and benefits, allocated overhead and pass-through costs. We expect that our cost of revenues will continue to increase in fiscal 2004 as revenue increases.

The decrease in the cost of revenues as a percentage of total revenues to 64.4% for the three months ended March 31, 2004 from 69.2% for the three months ended March 31, 2003 is primarily due to our increase in total revenues with a lesser increase in costs associated with project related tasks. The cost of revenues as a percentage of total revenues also fluctuates due to work-flow variations in the utilization of staff and the mix of services provided by us in any given period.

General and administrative expenses for the three months ended March 31, 2004 and 2002 were \$1,060,475 and \$913,197, respectively, an increase of \$147,278 or 16.1%. The increase is primarily due to an increase in personnel to support the growth in our service revenues and also includes approximately \$73,000 of expenses associated with CapMed. General and

**Table of Contents**

administrative expenses in each of the three months ended March 31, 2004 and 2003 consisted primarily of professional salaries and benefits, depreciation and amortization, professional and consulting services, office rent and corporate insurance. We expect that our general and administrative expenses will continue to increase in fiscal 2004 as revenue increases.

General and administrative expenses as a percentage of total revenues remained constant at 16.0% for the three months ended March 31, 2004 and 2003.

Sales and marketing expenses for the three months ended March 31, 2004 and 2003 were \$651,047 and \$451,215, respectively, an increase of \$199,832 or 44.3%. The increase is primarily due to an increase in personnel as we focus on gaining more market share and also includes approximately \$109,000 of expenses associated with CapMed. Sales and marketing expenses in each of the three months ended March 31, 2004 and March 31, 2003 were comprised of direct sales and marketing costs, professional salaries and benefits and allocated overhead. We expect that sales and marketing expenses will increase in fiscal 2004 as we continue to expand our market presence in the United States and Europe.

The increase in sales and marketing expenses as a percentage of total revenues to 9.8% for the three months ended March 31, 2004 from 7.9% for the three months ended March 31, 2003 is primarily due to increased personnel expenses.

Net interest income for the three months ended March 31, 2004 was \$16,698 and net interest expense for the three months ended March 31, 2003 was \$27,387, an increase of \$44,085 or 161.0%. This increase is primarily due to interest income earned on a higher average cash balance for the three months ended March 31, 2004 as compared to the three months ended March 31, 2003. Net interest income and expense for the three months ended March 31, 2004 and 2003 is comprised of interest income earned on our cash balance and interest expense incurred on equipment lease obligations and the Quintiles Note.

Income before income taxes was \$664,479 for the three months ended March 31, 2004 and \$366,562 for the three months ended March 31, 2003, an increase of \$297,917 or 81.3%. The increase was attributable to the increased revenues associated with an increase in services performed on projects for which we were contracted offset, in part, by the costs associated with increased staffing levels necessary to perform the newly contracted services.

The increase in income before income taxes as a percentage of total revenues to 10.0% for the three months ended March 31, 2004 from 6.4% for the three months ended March 31, 2003 is primarily due to increased revenues associated with an increase in services performed on projects for which we were contracted with a lesser increase in costs of revenue as a percentage of total revenues for the three months ended March 31, 2004.

Income tax provision for the three months ended March 31, 2004 and 2003 was \$268,988 and \$110,000, respectively, an increase of \$158,988 or 144.5%. The increase is primarily due to the increase in our estimated effective tax rate for 2004 of approximately 40% as compared to approximately 30% for the three months ending March 31, 2003.

**Table of Contents****Business Segments**

We have set forth certain financial information with respect to our two business segments, pharmaceutical contract services and CapMed, in Note 5 Business Segments to our Consolidated Financial Statements in this Form 10-QSB. The quarter ended March 31, 2004 is the first full quarter of operations of our CapMed business segment as we acquired the intellectual property of CapMed Corporation in November 2003. During the quarter ended March 31, 2004, we had CapMed segment sales of approximately \$5,000 and total costs and expenses of approximately \$182,000, consisting of approximately \$109,000 of sales and marketing expenses and approximately \$73,000 of general and administrative expenses.

**Liquidity and Capital Resources**

|  | <b>Three Months<br/>Ended<br/>March 31, 2004</b> | <b>Three Months<br/>Ended<br/>March 31, 2003</b> |
|--|--|--|
| Net cash(used in) provided by operating activities | \$ (1,039,810)                                   | \$ 1,220,685                                     |
| Net cash used in investing activities              | \$ (573,800)                                     | \$ (380,720)                                     |
| Net cash used in financing activities              | \$ (134,197)                                     | \$ (93,435)                                      |

At March 31, 2004, we had cash and cash equivalents of \$11,541,646. Working capital at March 31, 2004 was \$13,146,344.

Net cash used in operating activities for the three months ended March 31, 2004 was \$1,039,810 as compared to net cash provided by operating activities of \$1,220,685 for the three months ended March 31, 2003. This decrease is primarily due to the increase in accounts receivable of \$1,681,095 at March 31, 2004 from December 31, 2003, offset by the higher depreciation and amortization expense of \$428,446 and the provision for deferred income taxes of \$215,728.

Net cash used in investing activities represents our investment in capital and leasehold improvements. We currently anticipate that capital expenditures for the remainder of fiscal year ending December 31, 2004 will be approximately \$1,400,000. These expenditures represent additional upgrades in our networking, data storage and core laboratory capabilities for both our United States and European operations.

Net cash used in financing activities is primarily attributable to payments under equipment lease obligations and the Quintiles Note.

**Table of Contents**

The following table lists our cash contractual obligations as of March 31, 2004:

| <b>Contractual obligations</b>            | <b>Payments Due By Period</b> |                             |                     |                     |                          |
|---|-------------------------------|-----------------------------|---------------------|---------------------|--------------------------|
|   | <b>Total</b>                  | <b>Less than 1<br/>year</b> | <b>1-3 years</b>    | <b>4-5 years</b>    | <b>After 5<br/>years</b> |
| Long-term debt obligations                |                               |                             |                     |                     |                          |
| Capital lease obligations                 | \$ 1,230,163                  | \$ 612,886                  | \$ 617,277          |                     |                          |
| Facility rent operating leases            | \$ 5,301,188                  | \$ 939,743                  | \$ 2,757,663        | \$ 1,425,284        | \$ 178,498               |
| Purchase obligations                      |                               |                             |                     |                     |                          |
| Employment agreements                     | \$ 375,000                    | \$ 375,000                  |                     |                     |                          |
| Quintiles Note                            | \$ 624,997                    | \$ 624,997                  |                     |                     |                          |
| <b>Total contractual cash obligations</b> | <b>\$ 7,531,348</b>           | <b>\$ 2,552,626</b>         | <b>\$ 3,374,940</b> | <b>\$ 1,425,284</b> | <b>\$ 178,498</b>        |

On May 9, 2003, we renewed and amended our agreement with Wachovia Bank, National Association. The renewed and amended agreement is for a committed line of credit of \$2,000,000, collateralized by our assets. Interest is payable at Wachovia Bank's prime rate. The agreement requires us, among other things, to maintain a debt service coverage ratio not less than 1.25 to 1.00, measured annually and a liquidity ratio of not less than 2.00 to 1.00 at all times. The committed line of credit matures June 30, 2004 and may be renewed on an annual basis. During the three months ended and at March 31, 2004, we had no borrowings under the committed line of credit and are compliant with the debt covenants. On May 4, 2004, we executed a commitment letter with Wachovia Bank to renew and amend the committed line of credit to an unsecured \$5,000,000.

In connection with our acquisition of Intelligent Imaging, as of February 1, 2002, we are obligated to pay quarterly payments of principal of \$41,667 under the Quintiles Note, plus accrued interest thereon, and one payment of principal of \$500,000 on November 1, 2004, unless the Quintiles Note is previously converted into shares of our common stock. The Quintiles Note bears interest at the rate in effect on the business day immediately prior to the date on which payments are due under the Quintiles Note equal to the three-month LIBOR as published from time to time in The Wall Street Journal plus 3%, compounded annually based on a 365-day year. We have recorded the balance of the Quintiles Note of \$624,997 as a current liability.

We have neither paid nor declared dividends on our common stock since our inception and do not plan to pay dividends on our common stock in the foreseeable future.

We have not entered into any off-balance sheet transactions, arrangements or other relationships with unconsolidated entities or other persons that are likely to affect liquidity or the availability of or requirements for capital resources.



## **Table of Contents**

We anticipate that our existing capital resources together with cash flow from operations and borrowing capacity under the existing line of credit, will be sufficient to meet our foreseeable cash needs. However, we cannot assure you that our operating results will continue to achieve profitability on an annual basis in the future. The inherent operational risks associated with:

our ability to gain new client contracts;

the variability of the timing of payments on existing client contracts; and

other changes in our operating assets and liabilities

may have a material adverse affect on our future liquidity.

We may seek to raise additional capital from equity or debt sources in order to take advantage of unanticipated opportunities, such as more rapid expansion, acquisitions of complementary businesses or the development of new services. We cannot assure you that additional financing will be available, if at all, on terms acceptable to us.

Our fiscal 2004 operating plan contains assumptions regarding revenue and expenses. The achievement of our operating plan depends heavily on the timing of work performed by us on existing projects and our ability to gain and perform work on new projects. Project cancellation, or delays in the timing of work performed by us on existing projects or our inability to gain and perform work on new projects could have an adverse impact on our ability to execute our operating plan and maintain adequate cash flow. In the event actual results do not meet the operating plan, our management believes it could execute contingency plans to mitigate these effects. Our plans include additional financing, to the extent available, through the line of credit discussed above. Considering the cash on hand and based on the achievement of the operating plan and management's actions taken to date, management believes it has the ability to continue to generate sufficient cash to satisfy our operating requirements in the normal course of business for at least the next 12 months and the foreseeable future.

## **Changes to Critical Accounting Policies and Estimates**

Our critical accounting policies and estimates are set forth in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2003. As of March 31, 2004, there have been no changes to such critical accounting policies and estimates.

## **Item 3. Controls and Procedures.**

*Evaluation of disclosure controls and procedures.* Based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-14(c) and 15d-14(c) under the Exchange Act) as of March 31, 2004, our president and chief executive officer (principal executive officer) and our chief financial officer (principal accounting and financial officer) have concluded that our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and are operating in an effective manner.

*Changes in internal control over financial reporting.* There were no changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of our most recent evaluation.



**Table of Contents**

**PART II. OTHER INFORMATION.**

**Item 6. Exhibits and Reports on Form 8-K.**

(a) Exhibits.

- 31.1 Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of principal financial and accounting officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350.
- 32.2 Certification of principal financial and accounting officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350.

(b) Reports on Form 8-K.

On February 4, 2004, we furnished a Current Report on Form 8-K under Item 12, containing a copy of our earnings release for the fourth quarter and year ended December 31, 2003 (including financial statements).

On January 5, 2004, we filed a Current Report on Form 8-K under Item 9, reporting that certain of our directors entered into trading plans pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

**Table of Contents**

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-IMAGING TECHNOLOGIES, INC.

DATE: May 14, 2004

By: /s/ Mark L. Weinstein

---

Mark L. Weinstein, President and Chief Executive Officer  
(Principal Executive Officer)

DATE: May 14, 2004

By: /s/ Ted I. Kaminer

---

Ted I. Kaminer, Senior Vice President and  
Chief Financial Officer  
(Principal Financial and Accounting Officer)